• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

治疗性放射性金属:全球科学文献趋势分析(2008-2018 年)。

Therapeutic Radiometals: Worldwide Scientific Literature Trend Analysis (2008⁻2018).

机构信息

Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Ludovico Ariosto, 35-44121 Ferrara, Italy.

Nuclear Medicine Unit, University Hospital, Via Aldo Moro, 8-44124 Ferrara, Italy.

出版信息

Molecules. 2019 Feb 12;24(3):640. doi: 10.3390/molecules24030640.

DOI:10.3390/molecules24030640
PMID:30759753
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6385165/
Abstract

Academic journals have published a large number of papers in the therapeutic nuclear medicine (NM) research field in the last 10 years. Despite this, a literature analysis has never before been made to point out the research interest in therapeutic radionuclides (RNs). For this reason, the present study aims specifically to analyze the research output on therapeutic radiometals from 2008 to 2018, with intent to quantify and identify global trends in scientific literature and emphasize the interdisciplinary nature of this research field. The data search targeted conventional (I, Y, Lu, Re, Re, Sm, Sr, Er) and emergent (Cu, Sc, Ra, Ho, Tb, Tb, Pb/Bi, Ac, Bi, At, Sn) RNs. Starting from this time frame, authors have analyzed and interpreted this scientific trend quantitatively first, and qualitatively after.

摘要

在过去的十年中,学术期刊发表了大量关于治疗核医学(NM)研究领域的论文。尽管如此,以前从未进行过文献分析来指出治疗性放射性核素(RNs)的研究兴趣。出于这个原因,本研究专门旨在分析 2008 年至 2018 年治疗性放射金属的研究成果,旨在量化和确定科学文献中的全球趋势,并强调该研究领域的跨学科性质。数据搜索针对常规(I、Y、Lu、Re、Re、Sm、Sr、Er)和新兴(Cu、Sc、Ra、Ho、Tb、Tm、Pb/Bi、Ac、Bi、At、Sn)RNs。从这个时间框架开始,作者首先对这一科学趋势进行了定量分析和解释,然后进行了定性分析。

相似文献

1
Therapeutic Radiometals: Worldwide Scientific Literature Trend Analysis (2008⁻2018).治疗性放射性金属:全球科学文献趋势分析(2008-2018 年)。
Molecules. 2019 Feb 12;24(3):640. doi: 10.3390/molecules24030640.
2
Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods.通过计算方法对用于骨转移姑息治疗的11种不同放射性同位素进行比较分析。
Med Phys. 2014 Nov;41(11):114101. doi: 10.1118/1.4897240.
3
Therapeutic Radiometals Beyond Lu and Y: Production and Application of Promising α-Particle, β-Particle, and Auger Electron Emitters.镥和钇之外的治疗性放射性金属:有前景的α粒子、β粒子和俄歇电子发射体的生产与应用
J Nucl Med. 2017 Sep;58(Suppl 2):91S-96S. doi: 10.2967/jnumed.116.186825.
4
Tumour targeting with radiometals for diagnosis and therapy.放射性金属肿瘤靶向诊断与治疗。
Chem Commun (Camb). 2013 May 25;49(42):4720-39. doi: 10.1039/c3cc41554f.
5
Development of novel radionuclides for medical applications.用于医学应用的新型放射性核素的研发。
J Labelled Comp Radiopharm. 2018 Mar;61(3):126-140. doi: 10.1002/jlcr.3578. Epub 2017 Dec 29.
6
Production and Clinical Applications of Radiopharmaceuticals and Medical Radioisotopes in Iran.伊朗放射性药物与医用放射性同位素的生产及临床应用
Semin Nucl Med. 2016 Jul;46(4):340-58. doi: 10.1053/j.semnuclmed.2016.01.006.
7
Palliative treatment of metastatic bone pain with radiopharmaceuticals: A perspective beyond Strontium-89 and Samarium-153.放射性药物对转移性骨痛的姑息治疗:锶 - 89和钐 - 153之外的视角
Appl Radiat Isot. 2016 Apr;110:87-99. doi: 10.1016/j.apradiso.2016.01.003. Epub 2016 Jan 6.
8
Interdisciplinary Tasks in the Cyclotron Production of Radiometals for Medical Applications. The Case of Sc as Example.用于医学应用的回旋加速器生产放射性金属的跨学科任务。以 Sc 为例。
Molecules. 2019 Jan 26;24(3):444. doi: 10.3390/molecules24030444.
9
Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects.基于核衰变滞后效应的癌症治疗放射性核素的核异构体分离。
Sci Rep. 2017 Mar 13;7:44242. doi: 10.1038/srep44242.
10
Re-thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals.重新思考放射性金属同位素的作用:迈向治疗诊断放射性药物的未来概念。
J Labelled Comp Radiopharm. 2018 Mar;61(3):141-153. doi: 10.1002/jlcr.3582. Epub 2017 Dec 29.

引用本文的文献

1
Oldie but Goodie: Is Technetium-99m Still a Treasure Trove of Innovation for Medicine? A Patents Analysis (2000-2022).老而弥坚:锝-99m 仍然是医学创新的宝库吗?专利分析(2000-2022 年)。
J Med Chem. 2023 Apr 13;66(7):4532-4547. doi: 10.1021/acs.jmedchem.3c00148. Epub 2023 Apr 3.
2
Metal-Based Radiopharmaceuticals in Inorganic Chemistry.金属基放射性药物在无机化学中的应用。
Molecules. 2023 Mar 1;28(5):2290. doi: 10.3390/molecules28052290.
3
Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin.

本文引用的文献

1
In-house cyclotron production of high-purity Tc-99m and Tc-99m radiopharmaceuticals.利用内部回旋加速器生产高纯度的锝-99m及锝-99m放射性药物。
Appl Radiat Isot. 2018 Sep;139:325-331. doi: 10.1016/j.apradiso.2018.05.033. Epub 2018 May 30.
2
The Production of Ac-225.锕-225的产生
Curr Radiopharm. 2018;11(3):173-179. doi: 10.2174/1874471011666180418141357.
3
Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application.用于放射治疗诊断的钪和铽放射性核素:临床应用的当前发展状况
通过双重靶向 PSMA 和白蛋白来调节 Actinium-225 标记的大环衍生放射性缀合物的药代动力学特征。
Theranostics. 2022 Oct 17;12(17):7203-7215. doi: 10.7150/thno.78043. eCollection 2022.
4
Rhenium Radioisotopes for Medicine, a Focus on Production and Applications.铼放射性同位素在医学中的应用,聚焦于生产与应用。
Molecules. 2022 Aug 18;27(16):5283. doi: 10.3390/molecules27165283.
5
Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals.胆囊收缩素-2受体靶向放射性药物的临床前开发与临床转化进展
Cancers (Basel). 2021 Nov 18;13(22):5776. doi: 10.3390/cancers13225776.
6
A Universal Cassette-Based System for the Dissolution of Solid Targets.基于通用盒式系统的固体靶丸溶解技术
Molecules. 2021 Oct 16;26(20):6255. doi: 10.3390/molecules26206255.
7
Y/Lu-DOTATOC: From Preclinical Studies to Application in Humans.钇/镥-奥曲肽:从临床前研究到人体应用
Pharmaceutics. 2021 Sep 13;13(9):1463. doi: 10.3390/pharmaceutics13091463.
8
Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma.用于胶质母细胞瘤靶向放射性核素治疗的新型受体酪氨酸激酶途径抑制剂
Pharmaceuticals (Basel). 2021 Jun 29;14(7):626. doi: 10.3390/ph14070626.
9
Emerging Radionuclides in a Regulatory Framework for Medicinal Products - How Do They Fit?药品监管框架中的新兴放射性核素——它们如何适配?
Front Med (Lausanne). 2021 May 28;8:678452. doi: 10.3389/fmed.2021.678452. eCollection 2021.
10
Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy.放射性标记生长抑素类似物在癌症成像和治疗中的概述。
Molecules. 2020 Sep 2;25(17):4012. doi: 10.3390/molecules25174012.
Br J Radiol. 2018 Nov;91(1091):20180074. doi: 10.1259/bjr.20180074. Epub 2018 Jun 15.
4
α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1.α 发射器在放射治疗中的应用:从基础放射化学到临床研究——第 1 部分。
J Nucl Med. 2018 Jun;59(6):878-884. doi: 10.2967/jnumed.116.186338. Epub 2018 Mar 15.
5
Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.靶向 α 粒子治疗的进展。我们从体内发生器中了解到的放射性核素发射。
Molecules. 2018 Mar 5;23(3):581. doi: 10.3390/molecules23030581.
6
α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 2.α 发射器在放射治疗中的应用:从基础放射化学到临床研究 - 第 2 部分。
J Nucl Med. 2018 Jul;59(7):1020-1027. doi: 10.2967/jnumed.117.204651. Epub 2018 Mar 1.
7
Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials.靶向α与靶向β治疗癌症的全球比较:体外、体内和临床试验。
Crit Rev Oncol Hematol. 2018 Mar;123:7-20. doi: 10.1016/j.critrevonc.2018.01.001. Epub 2018 Jan 10.
8
Targeted and Nontargeted α-Particle Therapies.靶向和非靶向α粒子疗法。
Annu Rev Biomed Eng. 2018 Jun 4;20:73-93. doi: 10.1146/annurev-bioeng-062117-120931. Epub 2018 Jan 18.
9
Nuclear model analysis of excitation functions of α-particle induced reactions on In and Cd up to 60MeV with relevance to the production of high specific activity Sn.与高比活度锡的生产相关的、对高达60MeV的α粒子诱发的铟和镉反应激发函数的核模型分析。
Appl Radiat Isot. 2018 Feb;132:181-188. doi: 10.1016/j.apradiso.2017.12.002. Epub 2017 Dec 5.
10
Development of novel radionuclides for medical applications.用于医学应用的新型放射性核素的研发。
J Labelled Comp Radiopharm. 2018 Mar;61(3):126-140. doi: 10.1002/jlcr.3578. Epub 2017 Dec 29.